|
|
Worldwide Prescription Drug Market for Women's Health: Now and Future 2004-2009Published by: Fuji-Keizai USA, Inc. Published: Feb. 1, 2005 - 151 Pages Table of Contents1. Introduction to the Women’s Health Rx Drug Market 1.1 Overview 1.2 The Importance of Rx Drugs for Women’s Health 1.2.1 Drugs Can Help Prevent Or Cure Diseases Such As Osteoporosis, HIV/AIDS, and others. 1.2.2 Help their quality of life 1.2.3 Women Are Usually The Caregiver And Health Care Decision-Makers In Their Family. 1.2.4 Women Have Different Drug Needs Than Men. 1.2.5 Osteoporosis Is Another Silent Disease In Women’s Health. 1.2.6 Women Have Infertility Issues 1.2.7 And More 1.3 Main Drug Therapy Areas 1.3.1 Autoimmune Conditions 1.3.1.1 Rheumatoid Arthritis 1.3.1.2 Scleroderma 1.3.1.3 Sjogren’s Syndrome 1.3.1.4 Systemic Lupus Erythematosus 1.3.1.5 Multiple Sclerosis 1.3.1.6 Chronic Idiopathic Thrombocytopenic Purpura 1.3.1.7 Chronic Fatigue Syndrome 1.3.1.8 Fibromyalgia 1.3.2 Cancer 1.3.2.1 Breast Cancer 1.3.2.2 Cervical Cancer 1.3.2.3 Ovarian Cancer 1.3.2.4 Uterine Cancer (same as Endometrial) 1.3.3 Gynecological Infections and STDs 1.3.3.1 HIV/AIDS 1.3.3.2 Bacterial Vaginosis 1.3.3.3 Chlamydia 1.3.3.4 Genital Herpes (HSV-1&2) 1.3.3.5 HPV Infection 1.3.3.6 Gonorrhea 1.3.3.7 Hepatitis B and C 1.3.3.8 Pelvic Inflammatory Disease 1.3.3.9 Syphilis 1.3.3.10 Yeast (Candida) Infections 1.3.4 Menopause and Hormones 1.3.4.1 Endometriosis 1.3.4.2 Uterine Fibroids 1.3.4.3 Menopause 1.3.4.4 Amenorrhea 1.3.4.5 Dysmenorrhea 1.3.5 Osteoporosis 1.3.6 Reproductive Related Therapies 1.3.6.1 Contraception 1.3.6.2 Infertility 1.3.7 Female Sexual Dysfunction 1.3.8 Urologic and Kidney 1.3.8.1 Incontinence 1.3.8.2 Interstitial Cystitis 1.3.8.3 Urinary Tract Infections 2. Women’s Health Rx Drug Market View by Disease 2.2 Autoimmune Conditions 2.2.1 Overview 2.2.2 Autoimmune Incidence, Prevalence, Mortality & Growth by Indication 2.2.3 Autoimmune Drug Treatments, Makers & Revenue by Indication 2.2.4 Autoimmune New Drug Pipeline by Indication 2.2.5 Important Finding (Special Note) 2.3 Cancer 2.3.1 Overview 2.3.2 Cancer Incidence, Prevalence, Mortality & Growth by Indication 2.3.3 Cancer Drug Treatments, Makers & Revenue by Indication 2.3.4 Cancer New Drug R&D Pipeline/Commercial Implication by Indication 2.3.5 Important Finding (Special Note) 2.4 Gynecological Infections and STDs 2.4.1 Overview 2.4.2 Gynecological Infections Incidence, Prevalence, Mortality & Growth by Indication 2.4.3 Gynecological Infections Drug Treatments, Makers & Revenue by Indication 2.4.4 Gynecological Infections & STD Drug R&D Pipeline by Indication 2.4.5 Important Finding (Special Note) 2.5 Menopause and Hormones 2.5.1 Overview 2.5.2 Menopause & Hormones Incidence, Prevalence, Mortality & Growth 2003 2.5.3 Menopause & Hormone Drug Treatments, Makers & Revenue by Indication 2.5.4 Menopause & Hormone Drug R&D Pipeline by Indication 2.5.5 Important Finding (Special Note) 2.6 Osteoporosis 2.6.1 Overview 2.6.2 Osteoporosis Incidence, Prevalence, Mortality & Growth 2.6.3 Osteoporosis Drug Treatments, Makers & Revenue by Indication 2.6.4 Osteoporosis Drug R&D Pipeline & Commercial Implication Indication 2.6.5 Important Finding (Special Note) 2.7 Reproductive Related Therapies 2.7.1 Overview 2.7.2 Reproductive Incidence, Prevalence, Mortality & Growth by Indication 2.7.3 Reproductive Drug Treatments, Makers & Revenue by Indication 2.7.4 Reproductive Related Drug R&D Pipeline & Commercial Implication 2.7.5 Important Finding (Special Note) 2.8 Female Sexual Dysfunction 2.8.1 Overview 2.8.2 Female Sexual Dysfunction Incidence, Prevalence, Mortality & Growth by Indication 2.8.3 Female Sexual Dysfunction Drug Treatments, Makers & Revenue by Indication 2.8.4 Female Sexual Dysfunction Drug R&D Pipeline & Commercial Implication Indication 2.8.5 Important Finding (Special Note) 2.9 Urologic and Kidney 2.9.1 Overview 2.9.2 Urologic & Kidney Incidence, Prevalence, Mortality & Growth by Indication 2.9.3 Urologic & Kidney Drug Treatments, Makers & Revenue by Indication 2.9.4 Urologic & Kidney Drug R&D Pipeline & Commercial Implication Indication 2.9.5 Important Finding (Special Note) 3. Women’s Health Rx Drug Market Size Forecast by Disease 3.1 Total Market Size Forecast 2004E-2009P 3.1.2 Forecast Methodology 3.2 Market Size Forecast by Disease Segment 2004E-2009E 3.2.1 Forecast for ‘Autoimmune’ Segment 3.2.2 Forecast for ‘Cancer’ Segment 3.2.3 Forecast for ‘Gyn. Infections & STDs’ Segment 3.2.4 Forecast for ‘Female Sexual Dysfunction’ Segment 3.2.5 Forecast for ‘Menopause & Hormones’ Segment 3.2.6 Forecast for ‘Osteoporosis’ Segment 3.2.7 Forecast for ‘Reproductive Related’ Segment 3.2.8 Forecast for ‘Urological & Kidney’ Segment 3.3 WH Market Size Forecast by Disease Segment Breakdown 3.3.1 Forecast for ‘Autoimmune’ Indications 3.3.2 Forecast for ‘Cancer’ Indications 3.3.3 Forecast for ‘Female Sexual Dysfunction’ 3.3.4 Forecast for ‘Osteoporosis’ 3.3.5 Forecast for ‘Gynecological Infections & STD’ Indications 3.3.6 Forecast for the ‘Menopause and Hormones’ Indications 3.3.7 Forecast for the ‘Reproductive Related’ Indications 3.3.8 Forecast the ‘Urologic and Kidney’ Indications 3.3.9 WH Rx Market Size Forecast by Disease Segment Breakdown 2004-2009 ($M) 3.4 Share of Market by Disease Segments, 2005 & 2009 3.5 Market Size Forecast by WW Regions 3.6 Top Ranking 3-5 Drug Makers By Disease in WW WH Market 4. Profiles of Pharma & Biotech Companies in Women’s Health 4.1 Abbott Labs 4.2 Akzo Nobel 4.3 Allergan 4.4 Amgen 4.5 Astellas Pharma 4.6 AstraZeneca 4.7 Barr Labs 4.8 Bayer Healthcare 4.9 Biogen-Idec 4.10 Bristol-Myers Squibb 4.11 Chiron 4.12 Eli Lilly 4.13 Forest Laboratories 4.14 Genentech 4.15 Gilead Sciences 4.16 GlaxoSmithKline 4.17 Johnson & Johnson 4.18 Kyowa Hakko 4.19 Merck & Co 4.20 Novartis AG 4.21 Pfizer 4.22 Roche Group 4.23 Sanofi-Aventis 4.24 Schering AG 4.25 Schering-Plough 4.26 Serono AG 4.27 Shire Pharmaceutical 4.28 Solvay Pharmaceuticals 4.29 Takeda Chemical 4.30 Teva Pharmaceuticals 4.31 Warner Chilcott PLC 4.32 Watson Pharmaceuticals 4.33 Wyeth Pharmaceuticals 5. Appendix 5.1 Women’s Health Industry Web Links AbstractThis report looks at the worldwide prescription drug market for women's health and estimates the market outlook to 2009. The research study shows that, while the global economy has had its ups and downs, this report projects that the market will grow to about $116 billion in 2009 and will grow at a rate of about 16.6% (CAGR).Substantial unmet need exists in the women's health field and this report identifies the profitable marketing opportunities pharmaceutical companies can pursue by developing their businesses to include this market. In this report, we have identified diseases and conditions that particularly affect women at a rate of 55% or greater of the population of the industrialized world. As a result, women have some unique health needs. The women's broad range of healthcare needs makes them a more lucrative marketing target than men. Readers receive detailed data and analysis about important worldwide pharmaceutical industry developments. The research report discusses the main therapeutic areas of women’s diseases or conditions with a brief description of the disease; patient populations, incidence, prevalence and mortality; gives the drug market size by disease; market participants; current drug treatments and revenues; market trends; new Rx drug R&D pipeline and its potential year to launch. Pharmaceutical and biotech industry executives, product managers, marketers, planners, entrepreneurs, VCs, investors, academic researchers and consultants would find this report a useful information source. The report discusses the numerous women’s health pharmaceutical industry topics with interesting and useful findings. Over 37 tables and 15 figures illustrate the findings throughout this “must have” study.
Detailed information about the business and R&D activities of the top pharmaceutical and biotechnology companies is listed in many areas of this report - including more than 29 company profiles. Each profile includes financial data, current Rx drugs, 'female adjusted' revenue estimates by indication, late stage drugs in the pipeline and likely launch year.
|
|
|||
|
About MarketResearch.com
|
||||